1.XD2.Escrowed shares3.Valuation issues has gone way beyond normal valuation4.Technicals - Has had no correction in price whereas the market has had severalthis is not a u stock where it can go up up up
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%